Patents by Inventor Thomas P. Condon

Thomas P. Condon has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • COMPOSITIONS FOR MODULATING SOD-1 EXPRESSION
    Publication number: 20170037410
    Abstract: Disclosed herein are antisense compounds and methods for decreasing SOD-1 mRNA and protein expression. Such methods, compounds, and compositions are useful to treat, prevent, or ameliorate SOD-1 associated diseases, disorders, and conditions. Such SOD-1 associated diseases include amyotrophic sclerosis (ALS).
    Type: Application
    Filed: April 1, 2015
    Publication date: February 9, 2017
    Applicant: Ionis Pharmaceuticals, Inc.
    Inventors: Eric E. Swayze, Tracy Cole, Holly Kordasiewicz, Susan M. Freier, Thomas P. Condon, Edward Wancewicz, Trisha Lockhart, Timothy Vickers, Priyam Singh
  • Antisense modulation of superoxide dismutase 1, soluble expression
    Patent number: 9476051
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of superoxide dismutase 1, soluble. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding superoxide dismutase 1, soluble. Methods of using these compounds for modulation of superoxide dismutase 1, soluble expression and for treatment of diseases associated with expression of superoxide dismutase 1, soluble are provided.
    Type: Grant
    Filed: February 24, 2015
    Date of Patent: October 25, 2016
    Assignee: Ionis Pharmaceuticals, Inc.
    Inventors: C. Frank Bennett, Kenneth W. Dobie, Susan M. Freier, Thomas P. Condon, Ravi Jain, Richard Alan Smith, Don W. Cleveland
  • METHODS FOR SLOWING FAMILIAL ALS DISEASE PROGRESSION
    Publication number: 20100081705
    Abstract: Methods for slowing disease progression in an individual suffering from familial ALS are provided. Also provided are methods of increasing the survival time of an individual suffering from familial ALS. These methods employ antisense oligonucleotides targeted to SOD1, for use in inhibiting the expression of SOD1 in the central nervous system of an individual suffering from familial ALS.
    Type: Application
    Filed: September 24, 2009
    Publication date: April 1, 2010
    Inventors: C. Frank Bennett, Don W. Cleveland, Richard Alan Smith, Susan M. Freier, Thomas P. Condon
  • Antisense modulation of superoxide dismutase 1, soluble expression
    Patent number: 7678895
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of superoxide dismutase 1, soluble. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding superoxide dismutase 1, soluble. Methods of using these compounds for modulation of superoxide dismutase 1, soluble expression and for treatment of diseases associated with expression of superoxide dismutase 1, soluble are provided.
    Type: Grant
    Filed: June 7, 2006
    Date of Patent: March 16, 2010
    Assignee: Isis Pharmaceuticals, Inc.
    Inventors: C. Frank Bennett, Susan M. Freier, Thomas P. Condon
  • Methods for slowing familial ALS disease progression
    Patent number: 7622455
    Abstract: Methods for slowing disease progression in an individual suffering from familial ALS are provided. Also provided are methods of increasing the survival time of an individual suffering from familial ALS. These methods employ antisense oligonucleotides targeted to SOD1, for use in inhibiting the expression of SOD1 in the central nervous system of an individual suffering from familial ALS.
    Type: Grant
    Filed: September 21, 2006
    Date of Patent: November 24, 2009
    Assignee: Isis Pharmaceuticals, Inc.
    Inventors: C. Frank Bennett, Susan M. Freier, Thomas P. Condon
  • Oligonucleotide modulation of cell adhesion
    Publication number: 20090048435
    Abstract: Compositions comprising oligonucleotides which are specifically hybridizable with nucleic acids encoding cellular adhesion molecules intracellular adhesion molecule-1 (ICAM-1), vascular cell adhesion molecule-1 (VCAM-1) and endothelial leukocyte adhesion molecule-1 (ELAM-1) are disclosed. A series of double stranded RNA molecules targeting human ICAM-1 were designed and inhibition of RNA was measured. Oligonucleotides targeted to ICAM were effective in reducing airway hyperresponsiveness in mouse and monkey asthma models.
    Type: Application
    Filed: April 30, 2004
    Publication date: February 19, 2009
    Inventors: C. Frank Bennett, Thomas P. Condon
  • Antisense inhibition of adam10 expression
    Publication number: 20030211610
    Abstract: Antisense compounds, compositions and methods are provided for inhibiting the expression of ADAM10. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding ADAM10. Methods of using these compounds for inhibition of ADAM10 expression and for treatment of diseases associated with expression of ADAM10 are provided.
    Type: Application
    Filed: December 17, 2002
    Publication date: November 13, 2003
    Inventors: Thomas P. Condon, Shin Cheng Flournoy
  • Antisense modulation of macrophage inflammatory protein 3-alpha expression
    Publication number: 20030144225
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of macrophage inflammatory protein 3-alpha. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding macrophage inflammatory protein 3-alpha. Methods of using these compounds for modulation of macrophage inflammatory protein 3-alpha expression and for treatment of diseases associated with expression of macrophage inflammatory protein 3-alpha are provided.
    Type: Application
    Filed: December 28, 2001
    Publication date: July 31, 2003
    Inventors: James G. Karras, Thomas P. Condon
  • Compositions and methods for antisense inhibition of protein translation
    Publication number: 20020052331
    Abstract: Compositions and methods are provided for inhibiting the translation of a capped target mRNA. Antisense oligomers of the invention are targeted to the 5′ cap region of the target mRNA and include oligonucleosides, PNAS, or oligonucleotides modified at the 2′ position of the sugar. Preferably, said oligomers inhibit protein translation directly via interference with ribosome assembly.
    Type: Application
    Filed: March 15, 2001
    Publication date: May 2, 2002
    Inventors: Brenda Baker, C. Frank Bennett, Kevin P. Anderson, Thomas P. Condon
  • Antisense modulation of integrin &agr;4 expression
    Patent number: 6258790
    Abstract: Compositions and methods are provided for modulating the expression of integrin &agr;4. Antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding integrin &agr;4 are preferred. Methods of using these compounds for modulating integrin &agr;4 expression and for treatment of diseases associated with expression of integrin &agr;4 are also provided.
    Type: Grant
    Filed: August 19, 1999
    Date of Patent: July 10, 2001
    Assignee: Isis Pharmaceuticals, Inc.
    Inventors: C. Frank Bennett, Thomas P. Condon, Lex M. Cowsert
  • Antisense modulation of ADAM10 expression
    Patent number: 6228648
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of ADAM10. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding ADAM10. Methods of using these compounds for modulation of ADAM10 expression and for treatment of diseases associated with expression of ADAM10 are provided.
    Type: Grant
    Filed: March 17, 2000
    Date of Patent: May 8, 2001
    Assignee: Isis Pharmaceuticals, Inc.
    Inventors: Thomas P. Condon, Shin Cheng Flournoy
  • Enhanced antisense modulation of ICAM-1
    Patent number: 6111094
    Abstract: The present invention provides compositions and methods for detecting and modulating levels of intercellular adhesion molecule-1 (ICAM-1) proteins, including human ICAM-1.
    Type: Grant
    Filed: April 17, 1998
    Date of Patent: August 29, 2000
    Assignee: Isis Pharmaceuticals Inc.
    Inventors: C. Frank Bennett, Thomas P. Condon, Shin Cheng Flournoy
  • Antisense modulation of LFA-3
    Patent number: 6001651
    Abstract: Compositions and methods for the treatment and diagnosis of diseases or disorders amenable to treatment through modulation of expression of a nucleic acid encoding a lymphocyte function associated antigen 3 (LFA-3; also known as CD58) protein are provided.
    Type: Grant
    Filed: March 20, 1998
    Date of Patent: December 14, 1999
    Assignee: Isis Pharmaceuticals Inc.
    Inventors: C. Frank Bennett, Thomas P. Condon, Shin Cheng Flournoy, Jordan S. Pober, Weillie Ma
  • Antisense inhibition of integrin .alpha.4 expression
    Patent number: 5968826
    Abstract: Compositions and methods are provided for modulating the expression of integrin .alpha.4. Antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding integrin .alpha.4 are preferred. Methods of using these compounds for modulating integrin .alpha.4 expression and for treatment of diseases associated with expression of integrin .alpha.4 are also provided.
    Type: Grant
    Filed: October 5, 1998
    Date of Patent: October 19, 1999
    Assignee: Isis Pharmaceuticals Inc.
    Inventors: C. Frank Bennett, Thomas P. Condon, Lex M. Cowsert
  • Antisense modulation of PECAM-1
    Patent number: 5955443
    Abstract: Compositions and methods for the treatment and diagnosis of diseases or disorders amenable to treatment through modulation of expression of a nucleic acid encoding a platelet endothelial cell adhesion molecule-1 (PECAM-1; also known as CD31 antigen or endoCAM) protein are provided.
    Type: Grant
    Filed: March 19, 1998
    Date of Patent: September 21, 1999
    Assignee: Isis Pharmaceuticals Inc.
    Inventors: C. Frank Bennett, Thomas P. Condon, Shin Cheng Flournoy, Hong Zhang